Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 and Phase 2, First-in-Human, Multi-Center, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor

NCT07612891 is registered in ClinicalTrials.gov with Shenzhen Ionova Life Sciences Co., Ltd. as lead sponsor.

NCT NCT07612891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07612891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 and Phase 2, First-in-Human, Multi-Center, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
Lead sponsor
Shenzhen Ionova Life Sciences Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 4, 2025
Completion date
February 4, 2028
Enrollment
201 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid cancers, breast cancer (locally advanced or metastatic), endometrial cancer, metastatic (stage iv) breast cancer, ovarian cancer